NASDAQ$GEHC
GE HealthCare Technologies Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
GE HealthCare's financial performance in Q1 2024 showed a slight revenue decline but margin expansion, driven by productivity and pricing. The company reaffirmed its full-year guidance.
GE HealthCare reported a 1% decline in revenues, but organic revenue was approximately flat. Net income margin increased to 8.0%, and adjusted EBIT margin rose to 14.7%. Diluted EPS was $0.81, and adjusted EPS was $0.90. The company reaffirmed its full-year 2024 guidance.
- Revenues declined 1% year-over-year, but organic revenue growth was approximately flat.
- Net income margin increased to 8.0%, and adjusted EBIT margin rose to 14.7%.
- Diluted EPS was $0.81, and adjusted EPS was $0.90.
- Cash flow from operating activities was $419 million, and free cash flow was $274 million. Company reaffirmed full year 2024 guidance
Headline financials
Revenue & EPS history
GE HealthCare · Revenue · Quarterly
$4.65B
Revenue by segment
GE HealthCare · $4.01B total across 4 segments · Q3 2023
- Imaging$2.64B+4.7%65.8%
- Patient Care$764M+9.0%19.1%
- Pharma Diagnostics$589M+12.8%14.7%
- Other$19M+35.7%0.5%
Forward guidance
The Company is reaffirming full year 2024 guidance as follows:
Tailwinds
- Organic revenue growth of approximately 4% year-over-year.
- Adjusted EBIT margin in the range of 15.6% to 15.9%, reflecting an expansion of 50 to 80 basis points versus 2023 Adjusted EBIT margin of 15.1%.
- Adjusted effective tax rate (ETR) in the range of 23% to 25%.
- Adjusted EPS in the range of $4.20 to $4.35, representing 7% to 11% growth versus Adjusted EPS of $3.93 for 2023.
- Free cash flow of approximately $1.8 billion.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q1 2024
-0.2%
Avg return
Earnings day
+0.2%
Avg return
5 days after
-0.3%
Avg return
30 days after
50%
8 / 16 earnings
Positive
+11.5%
Q4 2021
Best reaction
-12.9%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -12.9% | -10.9% | -8.9% | |
| Q4 2025 | +6.4% | +0.4% | -5.7% | |
| Q3 2025 | -2.7% | -6.2% | +0.7% | |
| Q1 2025 | +3.3% | +1.9% | +3.6% | |
| Q4 2024 | +8.8% | +7.9% | -4.6% | |
| Q3 2024 | +2.4% | +2.0% | -2.4% | |
| Q2 2024 | +0.9% | -1.4% | +2.6% | |
| Q1 2024 | -12.0% | -10.6% | -11.7% | |
| Q4 2021 | +11.5% | +10.8% | +26.2% | |
| Q3 2023 | +8.1% | +13.3% | +8.4% | |
| Q3 2022 | +8.1% | +13.3% | +8.4% | |
| Q2 2023 | -4.0% | -3.4% | -15.1% | |
| Q1 2023 | -8.7% | -7.3% | -9.0% | |
| Q1 2022 | -8.7% | -7.3% | -9.0% | |
| Q2 2022 | -2.3% | +0.8% | +4.4% | |
| Q4 2022 | -0.8% | +0.7% | +7.4% | |
| Q3 2021 | — | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro